返回排名列表

Resmed Inc (RMD)

被低估
HealthcareMedical Instruments & SuppliesUnited States

基本面

75

价格

$221.10

市值

$32.04B

第一部分 · 这家公司值多少

概览

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$5.65B

最近12个月(截至2026/6/30)

净利润

$1.52B

最近12个月(截至2026/6/30)

自由现金流

$1.65B

股东权益合计

$6.59B

负债合计

$2.38B

流动比率

3.10

利息覆盖率

-

债务/EBITDA

0.40

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形被低估

公允价值

$347.45

当前价格

$221.10

安全边际

+36.4%

公允价值区间

$225.84 - $469.06

所用估值方法之间的离散区间,并非经过统计校准的置信区间。

估算方法

分析师目标价:$250.22
现金流折现法(DCF):$650.15
市盈率法(P/E):$187.86
格雷厄姆成长公式:$536.94
盈利能力价值(EPV):$117.55
合理市净率(P/B):$95.10
股息折现模型(戈登模型):$35.11
P/FFO(运营资金):$191.29
周期中段收益:$184.44
市销率法(P/S):$153.64
分析师共识:买入 (13B / 12H / 2S)
最近财报超预期:+1.09%

估值指标

市盈率(P/E)

21.20

ROE

23.1%

市净率(P/B)

4.84

P/FCF

19.34

毛利率

61.1%

ROIC

19.7%

盈利能力雷达图

价值创造(经济护城河)

ROIC

19.7%

WACC

8.5%

ROIC − WACC

+11.2 pp

ROIC 超过资本成本:公司正在为股东创造价值。

基本面分析标准

通过(19)

  • EPS shows upward trend
  • EPS CAGR 15.14%
  • Price CAGR 13.41%
  • ROIC 19.7%
  • Gross Margin 61.1%
  • P/FCF 19.34
  • Debt/Equity ratio
  • Operating Margin 33.4%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 23.9%
  • Revenue Growth 5Y 12.1%
  • PEG Ratio 0.79
  • Earnings Quality (OCF/NI) 1.19
  • Share Dilution -0.8%
  • Piotroski F-Score 7/9

未通过(7)

  • P/B Ratio 4.84
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Analyst Consensus 48% Buy
  • Earnings Surprise avg 0.8%
  • Net Margin Trend 26.9% vs 27.2%

不可用(2)

  • Dividend Payout NaN%
  • Interest Coverage

Piotroski F-评分

7/9

财务状况强健

score
criteria

盈利质量

1.19

高质量:盈利有现金流支撑

股权稀释

-0.8%

正在回购股份,对股东友好

机构持股

公司治理

管理团队

姓名职位年龄
Mr. Michael J. Farrell BE, MBA, SMCEO & Chairman53
Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScDFounder, Chair Emeritus & Non-Executive Director83
Mr. Michael J. RiderChief Legal Officer & Secretary67
Mr. Brett A. SandercockAdvisor58
Mr. Justin LeongChief Product Officer47
Mr. Aaron BloomerChief Financial Officer39
Mr. Alastair RobertsonChief Information Officer-
Ms. Sallilyn SchwartzChief Investor Relations Officer-
Mr. Jim EllisChief Compliance Officer-
Ms. Yvonne-Katrin PucknatChief Marketing Officer49

审计风险

1

董事会风险

7

薪酬风险

4

股东权利风险

3

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

文件

  • 年度报告(10-K)

    对公司业务、财务业绩和风险的年度概述。

    提交日期:2026-08-13

    查看文件
  • 季度报告(10-Q)

    最近三个月财务表现的最新情况。

    提交日期:2026-05-01

    查看文件
  • 临时报告(8-K)

    关于重大事件(如管理层变动或重要公告)的通知。

    提交日期:2026-09-01

    查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for RMD, sourced from Markets Gazette.

  • 3/10/2026POSITIVE
    3 Reasons Not to Sleep on ResMed Stock

    ResMed Inc., a prominent player in the sleep apnea and respiratory care market, is highlighted for its leadership in CPAP machines and other vital medical devices. The company's focus on improving respiratory health for millions globally positions it favorably within the healthcare sector. Investors are advised not to overlook ResMed's potential, suggesting a positive outlook driven by its established market position and ongoing innovation in medical technology. The company's products address a significant and growing health concern, underpinning its long-term value proposition.

  • 3/4/2026POSITIVE
    Here's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years

    ResMed Inc. (RMD) stock has delivered exceptional performance over the past 10 years, offering investors significant returns. While the article doesn't provide exact figures, the title "Here's How Much You Would Have Made" implies consistent and profitable growth. This is crucial for investors assessing the long-term potential of the medical device and sleep-care solutions sector. Past performance, while not guaranteeing future results, indicates ResMed's strong ability to generate shareholder value, potentially driven by product innovation, market expansion, and sound management.

via Markets Gazette